Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2011 Future Medicine Ltd. All rights reserved. All patients with metastatic colorectal cancer (mCRC) should be considered by a multidisciplinary team as the recent development of colorectal cancer management can bring the potential for a cure in patients with mCRC. Combination of 5-fluorouracil plus either oxaliplatin or irinotecan therapy is the standard first-line treatment for mCRC for those patients who can tolerate it as it can deliver the highest response rates. Combination of cetuximab with either oxaliplatin or irinotecan-based chemotherapy is a sensible strategy if metastases are limited and potentially could become resectable. The KRAS wild-type genotype is a strong predictor of efficacy of cetuximab, it is therefore essential to perform KRAS testing before cetuximab treatment is started. How long the initial 'induction treatment' should be and whether chemotherapy-free intervals are appropriate are issues that remain under consideration.

Original publication





Book title

Advances in the Pharmacological Management of Metastatic Colorectal Cancer

Publication Date



18 - 29